These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25109229)

  • 1. Framework for Optimal Global Vaccine Stockpile Design for Vaccine-Preventable Diseases: Application to Measles and Cholera Vaccines as Contrasting Examples.
    Thompson KM; Duintjer Tebbens RJ
    Risk Anal; 2016 Jul; 36(7):1487-509. PubMed ID: 25109229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategy, demand, management, and costs of an international cholera vaccine stockpile.
    Maskery B; DeRoeck D; Levin A; Kim YE; Wierzba TF; Clemens JD
    J Infect Dis; 2013 Nov; 208 Suppl 1():S15-22. PubMed ID: 24101640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal vaccine stockpile design for an eradicated disease: application to polio.
    Tebbens RJ; Pallansch MA; Alexander JP; Thompson KM
    Vaccine; 2010 Jun; 28(26):4312-27. PubMed ID: 20430122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral cholera vaccines and their impact on the global burden of disease.
    Wierzba TF
    Hum Vaccin Immunother; 2019; 15(6):1294-1301. PubMed ID: 30183486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal allocation of the limited oral cholera vaccine supply between endemic and epidemic settings.
    Moore SM; Lessler J
    J R Soc Interface; 2015 Oct; 12(111):20150703. PubMed ID: 26423441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is there enough vaccine to eradicate measles? An integrated analysis of measles-containing vaccine supply and demand.
    Smith G; Michelson J; Singh R; Dabbagh A; Hoekstra E; van den Ent M; Mallya A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S62-70. PubMed ID: 21666215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC.
    MMWR Recomm Rep; 1997 Jun; 46(RR-11):1-20. PubMed ID: 9213745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings.
    Hsiao A; Desai SN; Mogasale V; Excler JL; Digilio L
    Bull World Health Organ; 2017 Apr; 95(4):303-312. PubMed ID: 28479625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the national pediatric vaccine stockpile: supply shortages, health impacts and cost consequences.
    Shrestha SS; Wallace GS; Meltzer MI
    Vaccine; 2010 Aug; 28(38):6318-32. PubMed ID: 20638451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enabling implementation of the Global Vaccine Action Plan: developing investment cases to achieve targets for measles and rubella prevention.
    Thompson KM; Strebel PM; Dabbagh A; Cherian T; Cochi SL
    Vaccine; 2013 Apr; 31 Suppl 2():B149-56. PubMed ID: 23598476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measles and Rubella Global Strategic Plan 2012-2020 midterm review report: Background and summary.
    Orenstein WA; Cairns L; Hinman A; Nkowane B; Olivé JM; Reingold AL
    Vaccine; 2018 Jan; 36 Suppl 1():A35-A42. PubMed ID: 29307368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era.
    Desai SN; Pezzoli L; Alberti KP; Martin S; Costa A; Perea W; Legros D
    Hum Vaccin Immunother; 2017 Mar; 13(3):579-587. PubMed ID: 27813703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan.
    Abubakar A; Azman AS; Rumunu J; Ciglenecki I; Helderman T; West H; Lessler J; Sack DA; Martin S; Perea W; Legros D; Luquero FJ
    PLoS Med; 2015 Nov; 12(11):e1001901. PubMed ID: 26576044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Global Elimination Of Measles And Rubella With Strengthening Of Health Systems In Developing Countries.
    Andrus JK; Cochi SL; Cooper LZ; Klein JD
    Health Aff (Millwood); 2016 Feb; 35(2):327-33. PubMed ID: 26858388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining measles-containing vaccine demand and supply: an imperative to support measles mortality reduction efforts.
    Costa A; Henao-Restrepo AM; Marie Hall S; Jarrett S; Hoekstra EJ
    J Infect Dis; 2003 May; 187 Suppl 1():S22-8. PubMed ID: 12721888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The United States pediatric vaccine stockpile program.
    Lane KS; Chu SY; Santoli JM
    Clin Infect Dis; 2006 Mar; 42 Suppl 3():S125-9. PubMed ID: 16447134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The end of measles and congenital rubella: an achievable dream?
    Adamo G; Sturabotti G; D'Andrea E; Baccolini V; Romano F; Iannazzo S; Marzuillo C; Villari P
    Ann Ig; 2017; 29(1):1-26. PubMed ID: 28067934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of global vaccine stockpiles.
    Yen C; Hyde TB; Costa AJ; Fernandez K; Tam JS; Hugonnet S; Huvos AM; Duclos P; Dietz VJ; Burkholder BT
    Lancet Infect Dis; 2015 Mar; 15(3):340-7. PubMed ID: 25661473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?
    Clemens J; Holmgren J
    Curr Top Microbiol Immunol; 2014; 379():231-58. PubMed ID: 24402712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.